Warm Autoimmune Hemolytic Anemia – Executive Insights – Warm Autoimmune Hemolytic Anemia | Executive Insights | US/EU5 | 2022
Warm autoimmune hemolytic anemia (WAIHA), a type of autoimmune hemolytic anemia, is caused by increased erythrocyte destruction by IgG autoantibodies. Increasing the hemoglobin level to > 10 g/dL is the primary goal of treatment. With no approved drug therapy, corticosteroids, rituximab, and immunosuppressants form the mainstay of treatment for WAIHA. Two oral agents (Rigel’s fostamatinib and Incyte’s parsaclisib) and an antibody (J&J’s nipocalimab) are in Phase III development and lead the race to reach the market for the treatment of WAIHA. With a strong drug pipeline, the treatment landscape for WAIHA is expected to change significantly over the next ten years. The new drugs are not expected to replace the current standard of care, but they will carve out a niche for themselves by targeting certain subpopulation segments. With no approved drugs for WAIHA, drug developers have an opportunity to address this significant unmet need.
QUESTIONS ANSWERED
- What are the disease incidence and prevalence?
- What is the current standard of care for WAIHA treatment? What is the treatment gap?
- What are the key unmet needs? How can they be addressed by pipeline agents?
- What are the emerging therapies in development for WAIHA? When are they forecast to launch, and what are the estimated costs of treatment in different geographies?
- What are the key market drivers and limiters?
- What are the opinions of KOLs on different aspects of WAIHA?
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
GEOGRAPHY: United States, EU5
PRIMARY RESEARCH: 13 KOL interviews from November 2021 to January 2022
KEY COMPANIES COVERED: Janssen Research & Development, Sanofi, Rigel Pharmaceuticals, Incyte, Annexon
KEY DRUGS COVERED: Fostamatinib, nipocalimab, parsaclisib, isatuximab, rilzabrutinib, ANX005
Table of contents
- Warm Autoimmune Hemolytic Anemia - Executive Insights - Warm Autoimmune Hemolytic Anemia | Executive Insights | US/EU5 | 2022
- Warm Autoimmune Hemolytic Anemia | Executive Insights | US/EU5
Yogesh Shelke, M.B.A. (Pharm.), is an associate manager on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. Before joining Clarivate, he was instrumental in providing actionable insights to clients from various leading pharmaceutical companies regarding competitive intelligence, market sizing and forecasting, pipeline analysis, situational analysis, unmet need analysis, and market entry strategies in a variety of therapeutic areas. He holds a bachelor’s degree in pharmacy from Pune University and a master’s degree in pharmaceutical marketing from the National Institute of Pharmaceutical Education and Research in Mohali, India.
Graeme Green, M.Sc., Ph.D., is the head of the Cardiovascular, Metabolic, Renal, and Hematology (CMRH) group at Clarivate, where he leads a team of analysts investigating indications ranging from type 2 diabetes to chronic heart failure. With more than 14 years of market experience in this space, he has managed and authored a vast array of content. Using various forecasting and assessment methodologies, he has written indication-specific insight reports and provided analysis on market dynamics, drug development, and corporate strategy. Prior to moving to the pharmaceutical sector, he worked for a financial management consultancy. Dr. Green holds a Ph.D. in molecular medical microbiology and an M.Sc. in forensic science from King’s College London.